PIK3R1 is altered in 3.62% of malignant solid tumor patients with PIK3R1 Mutation present in 2.62% of all malignant solid tumor patients [4].

PIK3R1 Mutation is an inclusion criterion in 15 clinical trials for malignant solid tumor, of which 12 are open and 3 are closed. Of the trials that contain PIK3R1 Mutation and malignant solid tumor as inclusion criteria, 6 are phase 1 (4 open), 3 are phase 1/phase 2 (3 open), and 6 are phase 2 (5 open) [5].

PIK3R1 is altered in 2.59% of breast carcinoma patients with PIK3R1 Mutation present in 1.75% of all breast carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 8 clinical trials for breast carcinoma, of which 7 are open and 1 is closed. Of the trials that contain PIK3R1 Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), and 3 are phase 2 (3 open) [5].

PIK3R1 is altered in 5.11% of colorectal carcinoma patients with PIK3R1 Mutation present in 3.8% of all colorectal carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 4 clinical trials for colorectal carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PIK3R1 Mutation and colorectal carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

PIK3R1 is altered in 1.67% of non-small cell lung carcinoma patients with PIK3R1 Mutation present in 1.19% of all non-small cell lung carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 4 clinical trials for non-small cell lung carcinoma, of which 2 are open and 2 are closed. Of the trials that contain PIK3R1 Mutation and non-small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (0 open) [5].

PIK3R1 is altered in 2.58% of melanoma patients with PIK3R1 Mutation present in 2.21% of all melanoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 3 clinical trials for melanoma, of which 2 are open and 1 is closed. Of the trials that contain PIK3R1 Mutation and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [5].

PIK3R1 is altered in 1.65% of non-hodgkin lymphoma patients with PIK3R1 Mutation present in 1.18% of all non-hodgkin lymphoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 3 clinical trials for non-hodgkin lymphoma, of which 3 are open and 0 are closed. Of the trials that contain PIK3R1 Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 2 (2 open) [5].

PIK3R1 is altered in 26.49% of endometrial carcinoma patients with PIK3R1 Mutation present in 19.3% of all endometrial carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for endometrial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PIK3R1 is altered in 2.71% of squamous cell lung carcinoma patients with PIK3R1 Mutation present in 1.84% of all squamous cell lung carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 2.63% of ovarian carcinoma patients with PIK3R1 Mutation present in 1.59% of all ovarian carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for ovarian carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 1.91% of head and neck squamous cell carcinoma patients with PIK3R1 Mutation present in 1.56% of all head and neck squamous cell carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for head and neck squamous cell carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

PIK3R1 is altered in 1.43% of renal cell carcinoma patients with PIK3R1 Mutation present in 1.0% of all renal cell carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 Mutation and renal cell carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

PIK3R1 is altered in 0.96% of pancreatic carcinoma patients with PIK3R1 Mutation present in 0.82% of all pancreatic carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for pancreatic carcinoma, of which 1 is open and 1 is closed. Of the trials that contain PIK3R1 Mutation and pancreatic carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 1.34% of hepatocellular carcinoma patients with PIK3R1 Mutation present in 0.81% of all hepatocellular carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 2 clinical trials for hepatocellular carcinoma, of which 2 are open and 0 are closed. Of the trials that contain PIK3R1 Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

PIK3R1 is altered in 9.81% of glioblastoma patients with PIK3R1 Mutation present in 7.6% of all glioblastoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 9.16% of malignant glioma patients with PIK3R1 Mutation present in 7.3% of all malignant glioma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for malignant glioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and malignant glioma as inclusion criteria, 1 is early phase 1 (1 open) [5].

PIK3R1 is altered in 7.0% of anaplastic astrocytoma patients with PIK3R1 Mutation present in 5.6% of all anaplastic astrocytoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 3.41% of cancer patients with PIK3R1 Mutation present in 2.47% of all cancer patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and cancer as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 2.02% of gastric adenocarcinoma patients with PIK3R1 Mutation present in 1.78% of all gastric adenocarcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for gastric adenocarcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and gastric adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

PIK3R1 is altered in 1.94% of urothelial carcinoma patients with PIK3R1 Mutation present in 1.57% of all urothelial carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 2.37% of small cell lung carcinoma patients with PIK3R1 Mutation present in 1.51% of all small cell lung carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 2.03% of bladder carcinoma patients with PIK3R1 Mutation present in 1.5% of all bladder carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for bladder carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 2.26% of head and neck carcinoma patients with PIK3R1 Mutation present in 1.44% of all head and neck carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 1.74% of B-cell non-hodgkin lymphoma patients with PIK3R1 Mutation present in 1.31% of all B-cell non-hodgkin lymphoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

PIK3R1 is altered in 1.52% of lymphoma patients with PIK3R1 Mutation present in 1.16% of all lymphoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and lymphoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 2.9% of prostate carcinoma patients with PIK3R1 Mutation present in 1.11% of all prostate carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and prostate carcinoma as inclusion criteria, 1 is phase 3 (1 open) [5].

PIK3R1 is altered in 0.9% of liposarcoma patients with PIK3R1 Mutation present in 0.9% of all liposarcoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for liposarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and liposarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 is altered in 1.11% of hematologic and lymphocytic disorder patients with PIK3R1 Mutation present in 0.85% of all hematologic and lymphocytic disorder patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for hematologic and lymphocytic disorder, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and hematologic and lymphocytic disorder as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 0.75% of sarcoma patients with PIK3R1 Mutation present in 0.51% of all sarcoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains PIK3R1 Mutation and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

PIK3R1 is altered in 0.68% of hematopoietic and lymphoid malignancy patients with PIK3R1 Mutation present in 0.5% of all hematopoietic and lymphoid malignancy patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid malignancy, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and hematopoietic and lymphoid malignancy as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 0.47% of multiple myeloma patients with PIK3R1 Mutation present in 0.47% of all multiple myeloma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

PIK3R1 is altered in 0.59% of hematopoietic and lymphoid system neoplasm patients with PIK3R1 Mutation present in 0.44% of all hematopoietic and lymphoid system neoplasm patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 0.57% of thyroid gland carcinoma patients with PIK3R1 Mutation present in 0.32% of all thyroid gland carcinoma patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for aggressive systemic mastocytosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and aggressive systemic mastocytosis as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for chondrosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and chondrosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for classical hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and classical hodgkin lymphoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for desmoid-type fibromatosis, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and desmoid-type fibromatosis as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for Ewing sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and Ewing sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for mast cell leukemia, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and mast cell leukemia as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 0.15% of myelodysplastic syndromes patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic syndromes, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 is altered in 0.04% of myeloid neoplasm patients [4].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for myeloid neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and myeloid neoplasm as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for osteosarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and osteosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for pecoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and pecoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [5].

PIK3R1 Mutation is an inclusion criterion in 1 clinical trial for undifferentiated pleomorphic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 Mutation and undifferentiated pleomorphic sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].